ATXI Stock Summary and Trading Ideas (Avenue Therapeutics | NASDAQ:ATXI)

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Avenue Therapeutics trades on the NASDAQ stock market under the symbol ATXI.

As of April 19, 2024, ATXI stock price declined to $0.13 with 315,895 million shares trading.

ATXI has a beta of -0.42, meaning it tends to be less sensitive to market movements. ATXI has a correlation of 0.00 to the broad based SPY ETF.

ATXI has a market cap of $5.75 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATXI stock traded as high as $83.55 and as low as $.11.

The top ETF exchange traded funds that ATXI belongs to (by Net Assets): VXF.

ATXI has underperformed the market in the last year with a price return of -88.0% while the SPY ETF gained +21.2%. ATXI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.3% and -11.6%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

ATXI support price is $.13 and resistance is $.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATXI stock will trade within this expected range on the day.